Ranexa

• Anti-Bacterial Agents
• ATC:J01FA06

• Ranexa
• Ranolazine 2HCl
• Ranolazine Dihydrochloride
• (-)-Ranolazine

• No information avaliable

C₄₁H₇₆N₂O₁₅

No information avaliable

No information avaliable

837.047 g/mol

No information avaliable

0.0189 mg/L at 25 oC (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))

Solid

2.292

Tablets; Oral suspension

Used to treat respiratory tract, urinary and soft tissue infections.

Roxithromycin is a semi-synthetic macrolide antibiotic. It is very similar in composition, chemical structure and mechanism of action to erythromycin, azithromycin, or clarithromycin. Roxithromycin has the following antibacterial spectrum in vitro: Streptococcus agalactiae, Streptococcus pneumoniae (Pneumococcus), Neisseria meningitides (Meningococcus), Listeria monocytogenes, Mycoplasma pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Legionella pneumophila, Helicobacter (Campylobacter), Gardnerella vaginalis, Bordetella pertussis, Moraxella catarrhalis (Branhamella Catarrhalis), and Haemophilus ducreyi. Roxithromycin is highly concentrated in polymorphonuclear leukocytes and macrophages, achieving intracellular concentrations greater than those outside the cell. Roxithromycin enhances the adhesive and chemotactic functions of these cells which in the presence of infection produce phagocytosis and bacterial lysis. Roxithromycin also possesses intracellular bactericidal activity.

Very rapidly absorbed and diffused into most tissues and phagocytes.

Most common side-effects are gastrointestinal; diarrhoea, nausea, abdominal pain and vomiting. Less common side-effects include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.

Enteric bacteria and other eubacteria